Presented today at #MSToronto2026: The REMODEL-1 and REMODEL-2 studies find that remibrutinib was superior to teriflunomide in patients with relapsing multiple sclerosis, while maintaining a favourable safety profile.
Explore the research: spkl.io/60137kz2B
Thread
Nenhum Voo ainda